No Data
No Data
Beijing Tiantan Biological Products Corporation (600161.SH) will distribute 1.5 yuan per share with a 10-for-2 stock conversion ratio in 2023. The registration date is June 19th.
Beijing Tiantan Biological Products Corporation (600161.SH) has announced that the company will implement annual equity distribution for the year 2023, with a dividend of per share...
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Tiantan Biology (600161.SH): Affiliated companies obtained approval notices for drug supplementation applications and passed drug GMP compliance checks
Gelonghui, April 10 | Tiantan Biology (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd. recently received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The “human fibrinogen” developed by Chengdu Rongsheng complies with the relevant requirements for drug registration. At the same time, Chengdu Rongsheng's relevant production site has passed the drug GMP compliance inspection and obtained the “Drug GMP Site Inspection Results Notice” issued by the Sichuan Drug Administration. Chengdu Rongsheng has obtained the “Human Fibrinogen [Specification: 0.5g (25m1) /bottle]” drug supplement application approval
Liberal Arts Biotech (300294.SZ): No business-level cooperation with Tiantan Biotech
Gelonghui March 13 | Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the company has no business-level cooperation with Tiantan Biotech. The company has always followed industry benchmarks as an example.
Guosheng Securities: Supply and demand resonate and state-owned capital enters a new development cycle in the blood products industry
The supply and demand for blood products continues to expand, and the nearly 60 billion market still has room for growth.
Tiantan Biology (600161.SH): Affiliated company terminates clinical trials of drugs
Gelonghui, January 31 | Tiantan Biology (600161.SH) announced that the “intravenous cytomegalovirus human immunoglobulin (pH4)” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. is undergoing phase III clinical trial research. After comprehensive evaluation, the company decided to discontinue phase III clinical trial research and subsequent development of this drug. Intravenous cytomegalovirus human immunoglobulin (pH4) is a product independently developed by the company. It is mainly used to treat cytomegalovirus (CMV) emia and related diseases in immunodeficiency patients such as hematopoietic stem cell transplantation. Phase III clinical trials are ongoing. Based on domestic allogeneic hematopoietic stem cells
No Data